Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer.
Visani L, Livi L, Ratosa I, Orazem M, Ribnikar D, Saieva C, Becherini C, Salvestrini V, Scoccimarro E, Valzano M, Cerbai C, Desideri I, Bernini M, Orzalesi L, Nori J, Bianchi S, Morandi A, Meattini I. Visani L, et al. Among authors: valzano m. Radiother Oncol. 2022 Dec;177:40-45. doi: 10.1016/j.radonc.2022.10.023. Epub 2022 Oct 28. Radiother Oncol. 2022. PMID: 36349599
Stereotactic Re-irradiation in Recurrent Prostate Cancer after Previous Postoperative or Definitive Radiotherapy: Long-term Results after a Median Follow-up of 4 Years.
Francolini G, Loi M, Di Cataldo V, Detti B, Stocchi G, Masi L, Doro R, Scoccimarro E, Bellini C, Aquilano M, Allegra AG, Peruzzi A, Guerrieri B, Morelli I, Valzano M, Ciccone LP, Salvestrini V, Desideri I, Livi L. Francolini G, et al. Among authors: valzano m. Clin Oncol (R Coll Radiol). 2022 Jan;34(1):50-56. doi: 10.1016/j.clon.2021.11.002. Epub 2021 Nov 19. Clin Oncol (R Coll Radiol). 2022. PMID: 34810069
Use of an alfa-lipoic, Methylsulfonylmethane, Boswellia serrata and Bromelain dietary supplement (OPERA®) for aromatase inhibitors-related arthralgia management (AIA): a prospective phase II trial (NCT04161833).
Desideri I, Lucidi S, Francolini G, Meattini I, Ciccone LP, Salvestrini V, Valzano M, Morelli I, Angelini L, Scotti V, Bonomo P, Greto D, Terziani F, Becherini C, Visani L, Livi L. Desideri I, et al. Among authors: valzano m. Med Oncol. 2022 Jun 6;39(8):113. doi: 10.1007/s12032-022-01723-x. Med Oncol. 2022. PMID: 35666314 Clinical Trial.
Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cells of mCRPC patients undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial (NCT04188275).
Francolini G, Loi M, Ciccone LP, Detti B, Di Cataldo V, Pinzani P, Salvianti F, Salvatore G, Sottili M, Santini C, Frosini G, Visani L, Burchini L, Mattioli C, Allegra AG, Valzano M, Cerbai C, Aquilano M, Salvestrini V, Desideri I, Mangoni M, Meattini I, Livi L. Francolini G, et al. Among authors: valzano m. Med Oncol. 2022 Jun 10;39(8):119. doi: 10.1007/s12032-022-01756-2. Med Oncol. 2022. PMID: 35687207
Killing two birds with a stone: how to maximise benefit from metastasis-directed therapy and modern systemic treatment in oligometastatic hormone sensitive prostate cancer.
Francolini G, Di Cataldo V, Detti B, Simontacchi G, Loi M, Valzano M, Desideri I, Meattini I, Mangoni M, Livi L. Francolini G, et al. Among authors: valzano m. Clin Exp Metastasis. 2022 Dec;39(6):841-843. doi: 10.1007/s10585-022-10187-2. Epub 2022 Oct 15. Clin Exp Metastasis. 2022. PMID: 36242700
Radiosensitizing Effect of Trabectedin on Human Soft Tissue Sarcoma Cells.
Loi M, Salvatore G, Aquilano M, Greto D, Talamonti C, Salvestrini V, Melica ME, Valzano M, Francolini G, Sottili M, Santini C, Becherini C, Campanacci DA, Mangoni M, Livi L. Loi M, et al. Among authors: valzano m. Int J Mol Sci. 2022 Nov 18;23(22):14305. doi: 10.3390/ijms232214305. Int J Mol Sci. 2022. PMID: 36430780 Free PMC article.
Three Months' PSA and Toxicity from a Prospective Trial Investigating STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy-STARR (NCT05455736).
Francolini G, Garlatti P, Di Cataldo V, Detti B, Loi M, Greto D, Simontacchi G, Morelli I, Burchini L, Allegra AG, Frosini G, Ganovelli M, Salvestrini V, Olmetto E, Visani L, Becherini C, Valzano M, Carnevale MG, Roghi M, Serni S, Mattioli C, Desideri I, Livi L. Francolini G, et al. Among authors: valzano m. Cancers (Basel). 2023 Feb 3;15(3):992. doi: 10.3390/cancers15030992. Cancers (Basel). 2023. PMID: 36765948 Free PMC article.
Early biochemical outcomes following PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial (NCT05022914): preliminary results.
Francolini G, Ganovelli M, Di Cataldo V, Detti B, Caini S, Loi M, Simontacchi G, Desideri I, Greto D, Valzano M, Serni S, Vaggelli L, Salvestrini V, Visani L, Becherini C, Olmetto E, Franzese C, Baldaccini D, Scorsetti M, Sollini M, Chiti A, Meattini I, Valicenti RK, Livi L. Francolini G, et al. Among authors: valzano m. Clin Exp Metastasis. 2023 Apr;40(2):197-201. doi: 10.1007/s10585-023-10204-y. Epub 2023 Apr 3. Clin Exp Metastasis. 2023. PMID: 37012498 Free PMC article.
PSMA guided approach for bIoCHEmical relapse after prostatectomy- (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga-PSMA PET/CT within a prospective study.
Francolini G, Banini M, Di Cataldo V, Detti B, Caini S, Loi M, Simontacchi G, Desideri I, Greto D, Valzano M, Roghi M, Serni S, Vaggelli L, Salvestrini V, Visani L, Becherini C, Olmetto E, Franzese C, Baldaccini D, Scorsetti M, Sollini M, Chiti A, Meattini I, Valicenti RK, Livi L. Francolini G, et al. Among authors: valzano m. Prostate. 2023 Sep;83(12):1201-1206. doi: 10.1002/pros.24579. Epub 2023 Jun 8. Prostate. 2023. PMID: 37290915
30 results